摘要
目的:观察人参皂苷Rg3联合XELOX方案(奥沙利铂+卡培他滨)治疗晚期胃癌的近期疗效和安全性,同时探讨血清血管内皮细胞生长因子(VEGF)与该方案疗效的相关性。方法:45例Ⅳ期复治胃癌患者,随机分为2组,治疗组23例给予人参皂苷Rg3联合XELOX方案治疗,对照组22例单用XELOX方案治疗,至少2个周期。观察2组患者的客观有效率(RR)、KPS评分和安全性,并检测2组患者治疗前后VEGF水平。结果:治疗组和对照组的RR分别为43.5%和22.7%(χ2=4.6293,P<0.05)。2组患者治疗后KPS评分均提高(F组间=16.725,F时间=124.856,P均<0.01)、VEGF水平均下降(F组间=30.125,F时间=153.289,P均<0.01),以治疗组较明显(P<0.05)。2组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:人参皂苷Rg3联合XELOX方案治疗晚期胃癌耐受性好,安全有效,值得临床推广应用。
Aim： To investigate the short term effects and toxiciy of ginsenoside Rg3 combined with XELOX regimen for advanced carcinoma of stomach, and to explore the relationship between the serum vascular endothelial growth factor （VEGF） and the clinical effect of this regimen. Methods：A total of 45 patients with stage IV advanced carcinorna of stomach were randomly divided into two groups. The treatment group was treated with ginsenoside Rg3 ＋ XELOX regimen. The control group was treated with XELOX regimen alone. Both two groups were treated with 2 cycles at least of chemotherapy. The response rate（RR） ,Karnofsky score （KPS） and safety were observed. The level of serum VEGF was measured by using ELISA method before and after the treatment. Results： The RR was 43.5% in the treatment group,and 22.7% in control group（χ2 =4. 629 3 ,P 〈 0.05 ）. The KPS in treatment group was significantly higher than that in control group after treatment（ Fgroup = 16. 725, Ftime = 124. 856,P 〈 .01 ）. The level of serum VEGF in treatment group was significantly lower than that in control group after treatment（ Fgroup = 30. 125, Ftime = 153. 289 ,P 〈 0.01 ）. There were not significant differences in incidence of toxicity between two groups（P 〉 0.05）. Conclusion ： The ginsenoside Rg3 combined with XELOX regimen for advanced carcinoma of stomach tends to show a better chemotherapeutic effect and less toxicity than XELOX regimen alone.
出处
《郑州大学学报（医学版）》
CAS
北大核心
2009年第4期844-846,共3页
Journal of Zhengzhou University(Medical Sciences)
